Brind.
  1. The FDA approved the Biologics License Application (BLA) for LEQEMBI IQLIK on August 30, 2025, involving companies headquartered in Cambridge and Tokyo.
  2. Biogen and Eisai are involved in the LEQEMBI launch, with Biogen headquartered in Cambridge and Eisai in Tokyo.

Biogen shipped Leqembi to China for inventory optimization.

1 report, 1 independent Updated Jul 31
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Biogen shipped Leqembi to China for inventory optimization.

Who's involved

What this event is mainly about
ChinaBiogen

Keep exploring

Part of

Biogen and Eisai are involved in the LEQEMBI launch, with Biogen headquartered in Cambridge and Eisai in Tokyo. All 2 developments

Within The FDA approved the Biologics License Application (BLA) for LEQEMBI IQLIK on August 30, 2025, involving companies headquartered in Cambridge and Tokyo.

The entities involved

Coverage

Newest first; wire copies grouped
  • BenzingaBiogen Lifts Outlook As Rare Disease And Alzheimer's Drug Sales Accelerate Biogen Inc. (NASDAQ:BIIB) reported on Thursday that the second quarter of 2025 adjusted earnings per share were $5.47, up 4%